Lymphoma PDX Models

Identifying robust preclinical models for lymphoma is essential for the development of new therapies targeting this disease. Patient-derived xenograft (PDX) models provide a predictive preclinical model with true representation of the human heterogeneity providing an accurate approach to predicting an agent’s efficacy prior to entering the clinic. The CrownBio lymphoma PDX collection consists of many models, including both primary and metastatic models. More

PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. CrownBio’s HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.
MODEL NUMBER CANCER SUBTYPE # per page
LY0257 NHL (DLBCL, ABC, MYD88 L265P)CLICK TO VIEW
LY14019 NHLCLICK TO VIEW
LY2104 EBV transformed lymphomaCLICK TO VIEW
LY2118 EBV transformed lymphomaCLICK TO VIEW
LY2201 LymphomaCLICK TO VIEW
LY2214 NHL (DLBCL, GCB)CLICK TO VIEW
LY2219 EBV transformed lymphomaCLICK TO VIEW
LY2240 EBV transformed lymphomaCLICK TO VIEW
LY2264 NHL (DLBCL, ABC, MYD88 L265P)CLICK TO VIEW
LY2266 NHL (B cell, ABC/GCB)CLICK TO VIEW
LY2298 B cell lymphoma (ABC/GCB, MYD88 L265P)CLICK TO VIEW
LY2301 NHL (DLBCL, ABC)CLICK TO VIEW
LY2310 B cell lymphomaCLICK TO VIEW
LY2318 NHL (DLBCL, GCB)CLICK TO VIEW
LY2345 NHL (DLBCL, ABC/GCB)CLICK TO VIEW
LY3071 EBV transformed lymphomaCLICK TO VIEW
LY3148 Burkitt lymphomaCLICK TO VIEW
LY3463 B cell lymphomaCLICK TO VIEW
LY3604 NHL (DLBCL, ABC/GCB)CLICK TO VIEW
LY3654 Follicular lymphomaCLICK TO VIEW